Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective

Torre E, Di Matteo S, Martinotti C, Bruno GM, Cabrino A, Fogliati EL, Giusti A, Barbieri M, Bottaro LC, Colombo GL

ClinicoEconomics and Outcomes Research 2026, 18:585328

Published Date: 1 May 2026